<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339741</url>
  </required_header>
  <id_info>
    <org_study_id>PsoriasisVitaminD</org_study_id>
    <secondary_id>COA No. 057/2011</secondary_id>
    <nct_id>NCT01339741</nct_id>
  </id_info>
  <brief_title>Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency</brief_title>
  <official_title>The Efficacy of Vitamin D3 for the Treatment of Chronic Plaque Type Psoriatic Patients With Vitamin D Deficiency and Insufficiency: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <brief_summary>
    <textblock>
      The purpose of this research is to study whether vitamin D supplement can improve clinical
      outcome (PASI score) in psoriasis vulgaris with vitamin D insufficiency and deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While psoriasis is not a lethal disease, the disease itself can impact patients' quality of
      life. Nowadays there are several researches on vitamin D functions. Recently review article
      of vitamin D deficiency by Holick MF., stated that vitamin D can play a role in decreasing
      the risk of osteoporosis and other chronic diseases such as malignancy, autoimmune disease,
      infectious disease, cardiovascular disease, and psoriasis. Moreover, vitamin D effects on
      keratinocyte by decreasing abnormal cell proliferation, differentiation, apoptosis and
      controlling immunological process via the suppression of T-cell activation, regulation of
      cytokine secretion patterns, induction of regulatory T-cell, modulation of T-cell
      proliferation and interference with T-cell apoptosis.

      Thus, our objective is to look for other alternative treatment, which may have less side
      effects and acceptable clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI Score)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normal vitamin D level after replacement correlate with improved clinical outcome (PASI Score) of psoriasis vulgaris.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatologic Life Qualify Index (DLQI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normal vitamin D level after replacement correlates with better DLQI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3, oral supplement, 12 weeks</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, oral route, 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderately severe (PASI â‰¤ 10), chronic plaque type psoriasis vulgaris patient,
             who is a new case or has at least treatment-free period as following: 4 weeks for
             topical calcipotriol, topical corticosteroid or 8 weeks for systemic therapy (i.e.
             cyclosporine, acitretin, methotrexate) or 12 weeks for Psoralen Ultraviolet A (PUVA),
             phototherapy or biological treatment.

          -  Age 18-year-old to 70-year-old.

          -  Psoriasis vulgaris patient with vitamin D insufficiency or deficiency.

        Exclusion Criteria:

          -  Pregnancy or Lactating mother.

          -  Subject with history of major gastrointestinal surgery or gastric bypass surgery.

          -  Subject with history of pustular psoriasis.

          -  Subject with active psoriatic arthritis.

          -  Subject with prior phototherapy within the past 3 months.

          -  Subject with history of hypocholesterolemia (serum cholesterol &lt; 120 mg/dl) or primary
             hyperparathyroidism.

          -  Subject who regularly takes vitamin D supplement exceed 3,000 iu/day and high vitamin
             D diet, for example cod liver oil.

          -  Subject with liver disease, cystic fibrosis, Crohn's disease, celiac sprue, renal
             disease, pancreatic disease, and inflammatory bowel disease.

          -  Subject taking following medication: corticosteroid, orlistat, rifampicin, isoniazid,
             ketoconazole, statin, and cholestyramine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chotinij Lertphanichkul, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chotinij Lertphanichkul, M.D.</last_name>
    <phone>662-256-4000</phone>
    <phone_ext>4253</phone_ext>
    <email>sea_mile@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marisa Pongprutthipan, M.D.</last_name>
    <phone>662-256-4000</phone>
    <phone_ext>4253</phone_ext>
    <email>dr_marisa@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chotinij Lertphanichkul, M.D.</name>
      <address>
        <city>Patumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chotinij Lertphanichkul, M.D.</last_name>
      <phone>662-256-4000</phone>
      <phone_ext>4253</phone_ext>
      <email>sea_mile@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marisa Pongprutthipan, M.D.</last_name>
      <phone>662-256-4000</phone>
      <phone_ext>4253</phone_ext>
      <email>dr_marisa@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chotinij Lertphanichkul, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007 Jul 21;370(9583):263-71. Review.</citation>
    <PMID>17658397</PMID>
  </reference>
  <reference>
    <citation>Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010 Aug;146(8):891-5. doi: 10.1001/archdermatol.2010.186.</citation>
    <PMID>20713823</PMID>
  </reference>
  <reference>
    <citation>Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S57-61. Review.</citation>
    <PMID>12894127</PMID>
  </reference>
  <reference>
    <citation>Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039.</citation>
    <PMID>18423260</PMID>
  </reference>
  <reference>
    <citation>Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology. 1983 Dec;113(6):1950-7.</citation>
    <PMID>6196178</PMID>
  </reference>
  <reference>
    <citation>Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ. 1985 Mar;35(3-4):51-4.</citation>
    <PMID>4069059</PMID>
  </reference>
  <reference>
    <citation>Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review.</citation>
    <PMID>17634462</PMID>
  </reference>
  <reference>
    <citation>Soontrapa S, Soontrapa S, Bunyaratavej N, Rojanasthien S, Kittimanon N, Lektrakul S. Vitamin D status of Thai premenopausal women. J Med Assoc Thai. 2009 Sep;92 Suppl5:S17-20.</citation>
    <PMID>19891376</PMID>
  </reference>
  <reference>
    <citation>Su MJ, Bikle DD, Mancianti ML, Pillai S. 1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. J Biol Chem. 1994 May 20;269(20):14723-9.</citation>
    <PMID>7910167</PMID>
  </reference>
  <reference>
    <citation>Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev. 1993 Feb;14(1):3-19. Review.</citation>
    <PMID>8491153</PMID>
  </reference>
  <reference>
    <citation>Rigby WF, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest. 1984 Oct;74(4):1451-5.</citation>
    <PMID>6332829</PMID>
  </reference>
  <reference>
    <citation>Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001 Nov 1;167(9):4974-80.</citation>
    <PMID>11673504</PMID>
  </reference>
  <reference>
    <citation>Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000 Mar 1;164(5):2405-11.</citation>
    <PMID>10679076</PMID>
  </reference>
  <reference>
    <citation>May E, Asadullah K, ZÃ¼gel U. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):377-93. Review.</citation>
    <PMID>15584887</PMID>
  </reference>
  <reference>
    <citation>Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007 Jul;16(7):618-25. Review.</citation>
    <PMID>17576242</PMID>
  </reference>
  <reference>
    <citation>Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009 Jan;94(1):26-34. doi: 10.1210/jc.2008-1454. Epub 2008 Oct 14. Review.</citation>
    <PMID>18854395</PMID>
  </reference>
  <reference>
    <citation>Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282(3):164-7.</citation>
    <PMID>2164359</PMID>
  </reference>
  <reference>
    <citation>Bagot M, Charue D, Lescs MC, Pamphile RP, Revuz J. Immunosuppressive effects of 1,25-dihydroxyvitamin D3 and its analogue calcipotriol on epidermal cells. Br J Dermatol. 1994 Apr;130(4):424-31.</citation>
    <PMID>8186106</PMID>
  </reference>
  <reference>
    <citation>Bruce S, Epinette WW, Funicella T, Ison A, Jones EL, Loss R Jr, McPhee ME, Whitmore C. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol. 1994 Nov;31(5 Pt 1):755-9.</citation>
    <PMID>7929921</PMID>
  </reference>
  <reference>
    <citation>Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, Koh E, Kumahara Y. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol. 1986 Oct;115(4):421-9.</citation>
    <PMID>3022784</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <last_update_submitted>April 20, 2011</last_update_submitted>
  <last_update_submitted_qc>April 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chotinij Lertphanichkul, M.D.</name_title>
    <organization>Faculty of Medicine, Chulalongkorn University</organization>
  </responsible_party>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Vitamin D Insufficiency</keyword>
  <keyword>Vitamin D Supplement</keyword>
  <keyword>Psoriasis Area and Severity Index (PASI Score)</keyword>
  <keyword>Dermatologic Life Qualify Index (DLQI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

